Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) drives innovation in life sciences, diagnostics, and industrial technologies through cutting-edge scientific instruments and operational excellence. This page serves as a centralized hub for all official company announcements, press releases, and market-moving developments.
Investors and industry professionals will find timely updates on earnings reports, strategic acquisitions, and product innovations that shape Danaher's leadership across healthcare and industrial markets. Our curated news collection simplifies tracking regulatory filings, partnership announcements, and operational milestones.
Key content categories include quarterly financial results, R&D breakthroughs in diagnostic systems, and updates from Danaher's core segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Bookmark this page to stay informed about developments impacting the company's position in precision medicine and industrial automation.
On April 25, 2023, Danaher Corporation (NYSE: DHR) disclosed its Q1 2023 financial results. The company reported net earnings of $1.4 billion or $1.94 per diluted share, alongside non-GAAP adjusted earnings of $2.36 per share. Total revenues fell 7.0% year-over-year to $7.2 billion, attributed to reduced COVID-19 revenue, while core revenue decreased by 4.0%. However, the base business core revenue grew 6.0%. The operating cash flow for the quarter stood at $1.9 billion, with free cash flow at $1.7 billion. For Q2 and the full year, non-GAAP base business core revenue growth is projected to be in the mid-single digits. CEO Rainer M. Blair noted a strong start despite challenges, highlighting a robust business outlook.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
